hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Tibotec (part of Johnson & Johnson)

Tibotec website: www.tibotec.com  

🔎 Run a search for “Tibotec (part of Johnson & Johnson)”

Get RSS feed of these results

All stories

Article
18 July 2011
+ Français - Hide

Author: Médecins Sans Frontières

Selon un rapport publié aujourd'hui par Médecins Sans Frontières (MSF) lors de la Conférence de l'International AIDS Society à Rome, plusieurs compagnies pharmaceutiques ont interrompu les programmes de réduction du coût des médicaments antirétroviraux...

Read more

Article
25 April 2011

Johnson & Johnson takes heat from Doctors Without Borders for not sharing HIV drug patents [USA]

Author: Susan Todd, Star Ledger [USA]

Doctors without Borders criticized Johnson & Johnson today for refusing to make patents on three HIV drugs available to a program that would reduce the cost of the medicines in developing countries…"Johnson & Johnson…has chosen to turn its...

Read more

Article
28 January 2011

J&J Generics Deal May Speed AIDS Drug Access in Africa, India

Author: Alex Nussbaum, Bloomberg [USA]

...Tibotec Pharmaceuticals [part of Johnson & Johnson]...has agreed to let three generic drugmakers provide copies of [its experimental AIDS drug] in sub-Saharan Africa, India and parts of Asia if it’s approved by regulators...[T]hat could make...

Read more

Article
15 December 2009
+ Français - Hide

Author: AFP

Une "communauté de brevets" pour la production de médicaments à moindres coûts contre le sida va commencer à opérer à la mi-2010, a annoncé lundi soir la Facilité internationale d'achats de médicaments (Unitaid)... Cette création est le fruit de...

Read more

Article
5 June 2008

Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies [USA]

Author: Kaiser Daily HIV/AIDS Report [USA]

Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S..."We urge the other drug companies to follow [Boehringer's] and Gilead's lead and to freeze price...

Read more

Article
11 March 2008

Microbicide Developer Receives License for Novel HIV Microbicide Candidate from Merck & Co., Inc.

Author: International Partnerships for Microbicides

…Merck & Co., Inc., has agreed to provide a royalty-free license to the non-profit International Partnership for Microbicides (IPM) to develop a novel antiretroviral compound for use as a potential vaginal microbicide…“Merck deserves recognition...

Read more

Article
5 April 2007

Aspen to market last-resort Aids drug across Africa

Author: Samantha Enslin, Business Report [So. Africa]

Aspen plans to market a salvage treatment, Prezista, for Aids patients in 20 sub-Saharan African countries through a deal with Ireland's Tibotec Pharmaceuticals [a division of Johnson & Johnson (J&J)]...The deal was structured so that Aspen...

Read more

Story
1 January 2007
+ Français - Hide
Article
1 January 2007
+ Français - Hide

Author: Les Entreprises du Médicament [France]

[annexe présente exemples d’actions & partenariats des Entreprises du Médicament: Novartis, sanofi-aventis, MSD (Merck Sharp & Dohme, partie de Merck), Laboratoires Pierre Fabre, Bayer, Novo Nordisk (partie de Novo Group), GlaxoSmithKline,...

Read more

Article
1 December 2006

Pharma Companies Need to Keep Improving AIDS Response, Says ICCR and Nigerian Doctor

Author: William Baue, SocialFunds

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) produced the most thorough study of pharmaceutical company action on HIV/AIDS, documenting how the industry falls significantly short of best practice...The Business and Human...

Read more